Once the Food and Drug Administration approved Addyi, a failed antidepressant repackaged as a libido pill for women, drug-maker Valeant Pharmaceuticals bought the company selling Addyi for $1 billion. If they were expecting to cash in on a blockbuster drug, early sales aren’t very promising: in the first month, only 227 prescriptions for the drug have been written. [More]
